Can Erythropoietin Protect the Cerebral Blood Flow and Oxygenation During Simulated Dive?

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2005 by Rigshospitalet, Denmark.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Thomas Kjeld, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier:
NCT00265486
First received: December 12, 2005
Last updated: May 23, 2012
Last verified: August 2005
  Purpose

During facial cooling and especially during breath hold, can mammals - and also humans - elicit a so called dive reflex, causing bradycardia, peripheral vasoconstriction and centralization of blood flow to brain, lungs and heart but the reflex is suppressed by physical activity. The dive reflex can be elicited by breath hold alone and will be more pronounced during simultaneously facial cooling, but not by stimulation of other skin receptors.

The dive reflex has an oxygen conserving effect, because of intense vasoconstriction in both viscera and muscles, and simultaneously with reduction in cardiac output (CO). Therefore plasma lactate will rise, to compensate for the lesser regional blood flow. If one hyperventilates with 100 % oxygen, then the reflex can still be elicited, but it is more pronounced during asphyxia. Experienced sports divers, who has been diving for more than 7-10 years have reduced post apnea acidosis and oxidational stress, but probably also less sensitivity for progressive hypoxia and hypercapnia, because these individuals have a more pronounced dive reflex.

Transcranial Doppler ultrasonography (TCD) gives a reproducibly value for brain perfusion by continuously non-invasive real-time sampling. A single piezo-electrical transducer sends and collects ultrasound through the temporal region of the scull, where it is the thinnest. Hereby can the blood flow of arteria cerebri anterior, media (MCA) and posterior and basilaris be estimated.

With TCD it can be shown that the cerebral blood flow rises in MCA in healthy subjects during facial cooling, with normal ventilation, when resting in a supine position without affecting the systemic blood pressure. Single Photon Emission Computerized Tomography (SPECT)-scanning during normo-baric and hyperbaric pressure of professional divers breathing 100 % oxygen has shown to reduce the cerebral blood flow in several regions of the brain.

But it is yet unknown how brain blood flow and metabolism are affected by an "face immersion dive" and simultaneously prolonged physical activity, and hence a rise in lactate under hyperbaric pressure (3 meters), breathing atmospheric air, similar to the circumstances for trained scuba divers work.

Presumably it will cause a fall in brain blood flow and in time cognitive deficits.

Erythropoietin (rhEPO) is a well known drug, used as doping in sports for about 15 years. So far the only known enhancement in athletic achievement by rhEPO is caused by peripheral improvements and especially blood capability to transport oxygen to the working muscles; this has been documented by a rise in haematocrit. rhEPO has also a neuroprotective effect on neurons in patients with neuron damage caused by cerebral hypoxic ischeamia.

rhEPO work also on a series of cerebral mechanisms, including enhanced motor and spatial learning and more. Enhanced motor learning may improve the professional divers choices during work and may be also physical performance and mechanical efficiency. Intravenous injection of rhEPO will increase rhEPO in cerebrospinal fluids, since rhEPO is capable of crossing blood brain. All together this may indicate that rhEPO, not only works on physical performance, but also has effects on the brain. rhEPO has also an effect on the condition of cancer and dialysis patients, not only explained by merely increased hematocrit.

This project will add new knowledge in the understanding of the mechanisms of clinical use of rhEPO.

The purpose of this study is to investigate, how brain blood flow and metabolism are affected by face immersion dive and simultaneously breath hold during normo-baric and hyperbaric pressure (3 m depth) when breathing atmospheric air in trained sports divers. IL-6, HSP-72, lactate, ammonium and body-temperature will be measured. Brain and muscle oxygenation will be measured by near-infrared spectroscopi (NIRS). Furthermore we will investigate whether a small dose of rhEPO affects mentioned parameters during simulated dive in pressure chamber with facial cooling.

Hypothesis Brain blood flow in trained divers will be diminished during prolonged physical activity during simultaneously face immersion dive and breath hold under hyperbaric pressure.

There will be a release of IL-6 and HSP-72. Pretreatment with a small amount of rhEPO before prolonged physical activity during simulated dive has a protective effect on brain blood flow and oxygenation.


Condition Intervention
Healthy
Drug: Recombinant human Erythropoietin

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Erythropoietin Protect the Cerebral Blood Flow and Oxygenation During Simulated Dive?

Resource links provided by NLM:


Further study details as provided by Rigshospitalet, Denmark:

Estimated Enrollment: 12
Study Start Date: August 2005
Estimated Study Completion Date: July 2012
Estimated Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Recombinant human Erythropoietin
    Adm 100 U/kg sc 1 hour before completing exercise in protocol
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

12 healthy non-smoking free divers

Criteria

Inclusion Criteria:

  • Age 18-40
  • No smokers
  • Healthy, including no history of cardiopulmonary disease
  • Normal heart and lung stethoscopy
  • Active diving at least twice a week
  • V02max at least 15 METS
  • Signed and informed consent

Exclusion Criteria:

  • Smokers
  • Any condition needing drug treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00265486

Contacts
Contact: Thomas Kjeld, MD +4522361885 thomaskjeld@dadlnet.dk
Contact: Niels Secher, MD, DMSc, Prof +4535452242 niels.h.secher@rh.hosp.dk

Locations
Denmark
Rigshospitalet Recruiting
Copenhagen, Copenhagen East, Denmark, 2100
Contact: Niels H Secher, MD, DMSc, Prof    +4535452242    niels.h.secher@rh.hosp.dk   
Sponsors and Collaborators
Rigshospitalet, Denmark
Investigators
Principal Investigator: Thomas Kjeld, MD Rigshospitalet, dept of aneasthesiolgy, 2042, Blegdamsvej, 2100 CPH, DK
  More Information

Publications:

Responsible Party: Thomas Kjeld, 1. reservelæge, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier: NCT00265486     History of Changes
Other Study ID Numbers: KF 01 271889
Study First Received: December 12, 2005
Last Updated: May 23, 2012
Health Authority: Denmark: Ethics Committee
Denmark: Danish Dataprotection Agency

Keywords provided by Rigshospitalet, Denmark:
Divers
Brain
Flow
Blood
EPO
Dive
reflex

Additional relevant MeSH terms:
Epoetin alfa
Hematinics
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 30, 2014